Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Sharp Corporation
  6. News
  7. Summary
    6753   JP3359600008

SHARP CORPORATION

(6753)
  Report
Delayed Japan Exchange  -  01:00:00 2023-01-27 am EST
1073.00 JPY   +1.61%
01/12Sharp acquires 'AA' in MSCI ESG Ratings
AQ
01/11Sharp : acquires "AA" in MSCI ESG Ratings
PU
01/05Sharp : Announces Launch of Flagship 4K TV, AQUOS XLED, in U.S. in Spring 2023
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sharp Corporation - World's first 1 report, the potential effect of Plasmacluster Technology on reducing viscous airway mucus that may relieve asthma symptoms using airway stem cell culture

10/14/2022 | 10:25am EST

Dr. Munemasa Mori, Principal Investigator and Assistant Professor of Medicine Columbia Center for Human Development, Department of Medicine at Columbia University in New York, U.S., is an expert in respiratory medicine and stem cell research.

Dr. Mori and his investigative team have verified the effect of Sharp Corporation's Plasmacluster technology on long-term cultured human airway stem cells and confirmed its potential to decrease viscous airway mucus secretion, a problem in asthma patients, suggesting that this technology may help alleviate respiratory tract symptoms related to airway conditions such as asthma.

Airway epithelial cells 2 line the luminal surface of the respiratory tract from the nasal cavity to the lungs. The airway epithelium plays a critical role in mucus clearance by expelling foreign substances through the mucus secretion from secretory cells and the unidirectional beating of motile ciliated cells. The study design investigated the effects of ions on the respiratory tract. Briefly, human airway tissue stem cells were first induced to differentiate into ciliated and secretory epithelial cells over the course of one month. The cultured cells formed a sheet-like structure and were then exposed to Plasmacluster ions for a maximum of 24 hours.

Dr. Mori's team did not observe obvious gross morphological changes in the cells or a sign of cell damage. Instead, quantitative gene expression analysis3 suggested a decrease in the marker linked with highly-viscous mucus associated with impaired breathing in the respiratory tract of asthma patients and an increase in the marker linked with the smooth secretory protein related to low-viscosity mucus that helps improve breathing. These changes may lead to symptom relief by improving airway mucus secretion, a significant problem in asthma patients. To date, Sharp has demonstrated the effectiveness of Plasmacluster technology in suppressing mite allergens that cause airway problems. Since this test was performed with equipment where no allergens such as dust mites and pollen were present, it suggests that Plasmacluster ions' effects may also contribute to benefit cells directly.

Sharp will further continue to verify the effects on cells and their mechanisms.

In addition to measures to counter SARS-CoV-2, Dr. Mori was interested in the overall effects of Plasmacluster ions on the respiratory system. Dr. Mori's team conducted the experiments independently at Columbia University using Plasmacluster technology equipment provided by Sharp.

For more than 20 years, Sharp has promoted academic marketing 4 to demonstrate the effectiveness of Plasmacluster technology at independent third-party testing institutions in Japan and overseas. Thus far, numerous independent testing organizations have proven its efficacy in suppressing the activity of harmful substances, including mite allergens, as well as clinical effectiveness in reducing bronchial inflammation levels in children with asthma and prevention and treatment of atopic dermatitis in mice. At the same time, Sharp has continued to verify the safety of Plasmacluster technology over the course of many years.

With the discovery of potential new effects of Plasmacluster technology, which may lead to relieving asthma symptoms in the human respiratory tract, Sharp will continue to demonstrate the effectiveness of Plasmacluster technology actively.

(C) 2022 Electronic News Publishing, source ENP Newswire

All news about SHARP CORPORATION
01/12Sharp acquires 'AA' in MSCI ESG Ratings
AQ
01/11Sharp : acquires "AA" in MSCI ESG Ratings
PU
01/05Sharp : Announces Launch of Flagship 4K TV, AQUOS XLED, in U.S. in Spring 2023
PU
2022Sharp at CES 2023
BU
2022Cues From Wall Street Elevate Tokyo Stock Market
MT
2022Sharp : to Take Part in CES 2023, Major US Tech Event
PU
2022Wall Street Cues, Recession Concerns Undercut Tokyo Stock Market
MT
2022Stronger Yen Sends Export Issues, Tokyo Shares Lower
MT
2022Japanese shares rise on Wall Street gains, robust outlook
RE
2022Japanese shares rise on Wall Street gains, robust corporate outlook
RE
More news
Analyst Recommendations on SHARP CORPORATION
More recommendations
Financials
Sales 2023 2 553 B 19 649 M 19 649 M
Net income 2023 13 797 M 106 M 106 M
Net Debt 2023 411 B 3 162 M 3 162 M
P/E ratio 2023 50,0x
Yield 2023 3,15%
Capitalization 697 B 5 362 M 5 362 M
EV / Sales 2023 0,43x
EV / Sales 2024 0,42x
Nbr of Employees 47 941
Free-Float 33,9%
Chart SHARP CORPORATION
Duration : Period :
Sharp Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SHARP CORPORATION
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 11
Last Close Price 1 073,00 JPY
Average target price 845,45 JPY
Spread / Average Target -21,2%
EPS Revisions
Managers and Directors
Po-Hsuan Wu President, CEO & Representative Director
Mototaka Taneya Managing Executive Officer, GM-R&D Business
Yasuo Himeiwa Independent Outside Director
Yutaka Nakagawa Independent Director
Masahiro Okitsu Representative Director & Executive Vice President
Sector and Competitors
1st jan.Capi. (M$)
SHARP CORPORATION13.55%5 362
SONY GROUP CORPORATION15.89%110 527
PANASONIC HOLDINGS CORPORATION9.95%21 936
LG ELECTRONICS INC.13.41%13 608
SHENZHEN MTC CO., LTD.10.89%2 583
CASIO COMPUTER CO., LTD.1.64%2 513